Pharma Gets 340B Appeals Court Victory But More Decisions Are Pending; Will Congress Step In?
Third Circuit is first of three federal appeals courts to issue a decision in multiple lawsuits over drug companies’ 340B contract pharmacy restrictions, which have led to conflicting lower court rulings on whether such restrictions are unlawful.
You may also be interested in...
340B Better Together? PhRMA Partners With Community Health Centers On Legislative Reforms
PhRMA's collaboration with the provider group may help alleviate concerns that legislators' pursuit of pharma-backed 340B reforms would pit lawmakers against hospitals that serve as a safety net for vulnerable patients.
340B Contract Pharmacy Restrictions Slowed Program’s 2021 Spending Trajectory, But Not Much
Manufacturer restrictions on discounts to contract pharmacies may have depressed sales for 340B-discounted diabetes drugs in 2021. But sales in other categories, including oncology, immunology and arthritis drugs, were up by 20% to 40%.
340B Court Ruling Offers Manufacturers Short-Term Reprieve In Contract Pharmacy Dispute
Federal court vacates enforcement letter to Lilly from HRSA, but the decision was not completely favorable to pharma. It also offers the view that the law does not allow manufacturers to restrict 340B discounts to hospitals using multiple contract pharmacies.